A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.
Antibodies, Monoclonal, Humanized
/ pharmacokinetics
Antineoplastic Agents, Immunological
/ pharmacokinetics
Biomarkers, Tumor
/ blood
Humans
Immunoassay
/ methods
Multiple Myeloma
/ blood
Myeloma Proteins
Recombinant Proteins
/ administration & dosage
Signaling Lymphocytic Activation Molecule Family
/ administration & dosage
Elotuzumab
Immunofixation electrophoresis
Monoclonal antibody
Multiple myeloma
Therapeutic
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
26
06
2020
accepted:
15
01
2021
revised:
14
01
2021
pubmed:
29
1
2021
medline:
22
6
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Negative immunofixation electrophoresis (IFE) of serum and/or urine is a diagnostic marker for determining a complete response (CR) after immunotherapy for multiple myeloma (MM). However, residual therapeutic antibodies such as elotuzumab (IgG-κ), can compromise IFE evaluation when the affected immunoglobulins belong to the same IgG-κ subclass. We thus sought to develop a simple and rapid method to treat patient serum before IFE to distinguish the residual elotuzumab. Serum samples from patients receiving elotuzumab were treated with a predetermined amount of soluble signaling lymphocyte activation molecule F7 (SLAMF7) protein and then subjected to conventional IFE testing. We tested our method in samples from 12 patients. The IgG-κ band in IFE disappeared or shifted after elotuzumab treatment in four patients with no bone marrow minimal residual disease and normalized free light chain, whereas seven patients with any sign of residual MM showed a remaining IgG-κ band after treatment. One-hour incubation of samples with 6-9 molar excess soluble SLAMF7 before IFE was sufficient to distinguish residual elotuzumab in 11 of 12 samples. This simple method does not require special reagents, can be performed in most clinical laboratories, and enables differentiation between patients with a CR and those requiring further treatment.
Identifiants
pubmed: 33507526
doi: 10.1007/s12185-021-03088-9
pii: 10.1007/s12185-021-03088-9
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Myeloma Proteins
0
Recombinant Proteins
0
SLAMF7 protein, human
0
Signaling Lymphocytic Activation Molecule Family
0
elotuzumab
1351PE5UGS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-479Références
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.
doi: 10.1056/NEJMra1011442
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
doi: 10.1038/nrdp.2017.46
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
doi: 10.1016/S1470-2045(16)30206-6
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–24.
doi: 10.1158/1535-7163.MCT-09-0483
Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–37.
doi: 10.1182/blood-2007-08-107292
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.
doi: 10.1056/NEJMoa1505654
Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–5.
doi: 10.1200/JCO.2011.37.7069
FDA. Prescribing information of Empliciti
Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, et al. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin Biochem. 2018;51:66–71.
doi: 10.1016/j.clinbiochem.2016.09.015
Tang F, Malek E, Math S, Schmotzer CL, Beck RC. Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab. Am J Clin Pathol. 2018;150(2):121–9.
doi: 10.1093/ajcp/aqy037
Thoren KL, Pianko MJ, Maakaroun Y, Landgren CO, Ramanathan LV. Distinguishing drug from disease by use of the hydrashift 2/4 daratumumab assay. J Appl Lab Med. 2019;3(5):857–63.
doi: 10.1373/jalm.2018.026476
McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095–104.
doi: 10.1515/cclm-2015-1031
van de Donk NW, Otten HG, El Haddad O, Axel A, Sasser AK, Croockewit S, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54(6):1105–9.
pubmed: 26812873
Liu L, Shurin MR, Wheeler SE. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis. Clin Biochem. 2020;75:40–7.
doi: 10.1016/j.clinbiochem.2019.10.011
Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP. Development and validation of electrochemiluminescence assays to measure free and total sSLAMF7 in human serum in the absence and presence of elotuzumab. AAPS J. 2016;18(4):989–99.
doi: 10.1208/s12248-016-9912-3
Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: The proteomics protocols handbook. Totowa: Humana Press; 2005.
FDA. Prescribing information of daratumumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761036s013lbl.pdf . Accessed 8 Mar 2020.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, et al. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget. 2018;9(78):34784–93.
doi: 10.18632/oncotarget.26196